MDMA-assisted psychotherapy is expected to receive FDA approval by 2022, following successful Phase 3 trials.
The Food and Drug Administration (FDA) tapped MDMA as a “breakthrough therapy” to treat post-traumatic stress disorder three years ago. This was seen as monumental because, like cannabis, MDMA is classified as a Schedule I drug by the Drug Enforcement Agency (DEA). That designation is given to drugs “with no currently accepted medical use and a high potential for abuse.”
Fast forward to the present day and the Multidisciplinary Association for Psychedelic Studies (MAPS), the organization behind the MDMA research, is experiencing rapid success with their Phase 3 clinical trials examining how MDMA can treat PTSD. According to MAPS founder Rick Doblin, the FDA is set to approve MDMA-assisted therapy for PTSD by 2022. The organization believes such treatment will become widely available the following year.
To be clear, this research doesn’t mean dropping MDMA acts …